ARTURO PEREIRA, M.D.; EMILIO MONTSERRAT, M.D.; FRANCISCO CERVANTES, M.D.; ClRIL ROZMAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Despite advances in the treatment of large-cell non-Hodgkin's lymphomas (1), patients who have relapses after chemotherapy still have a poor outcome with the presently available "rescue" regimens (2). Because the possibility of attaining a cure seems to rely on the initial chemotherapy, the identification of presenting factors that allow the clinician to select the best first-line treatment is a matter of great importance. In the June issue, Shipp and coworkers (3) proposed a prognostic classification, derived from a multivariate analysis of patients' pretreatment characteristics, that could predict the response to M-BACOD or m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide,
PEREIRA A, MONTSERRAT E, CERVANTES F, ROZMAN C. Advanced Lymphoma and CHOP Chemotherapy. Ann Intern Med. ;105:631. doi: 10.7326/0003-4819-105-4-631_2
Download citation file:
Published: Ann Intern Med. 1986;105(4):631.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use